The emerging context for advances in comparative effectiveness assessment.
The call for an entity for independent assessment and guidance on alternative medical interventions is timely. The emergence of four developments underscores the importance and sets the stage for progress: an improving evidence base; growing recognition of the importance of variation in the effectiveness of treatments across patients; recent emphasis on transparency; and growing adoption of pay-for-performance initiatives. To advance progress on these issues, the Institute of Medicine (IOM) has convened a Roundtable on Evidence-based Medicine. The roundtable is exploring ways to improve the development of evidence, the thoroughness with which it is applied, and the mechanisms for increasing national capacity for the work.
Rowe
John W
JW
Department of Health Policy and Management, Mailman School of Public Health, Columbia University. jwr2108@columbia.edu
Cortese
Denis A
DA
McGinnis
J Michael
JM
D003362:Cost-Benefit Analysis; D004341:Drug Evaluation / Q000191:economics*; D019317:Evidence-Based Medicine; D006302:Health Services Research / Q000458:organization & administration*; D006801:Humans; D007253:Information Centers / Q000458:organization & administration*; D017146:Models, Organizational; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D017149:Private Sector; D011785:Quality Assurance, Health Care / Q000191:economics; D012052:Reimbursement, Incentive; D012941:Social Responsibility; D013673:Technology Assessment, Biomedical / Q000191:economics / Q000458:organization & administration*; D014481:United States